These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 8903475

  • 1. Modulation of doxorubicin cytotoxicity by ethacrynic acid.
    Awasthi S, Singhal SS, He N, Chaubey M, Zimniak P, Srivastava SK, Singh SV, Awasthi YC.
    Int J Cancer; 1996 Nov 04; 68(3):333-9. PubMed ID: 8903475
    [Abstract] [Full Text] [Related]

  • 2. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines.
    Rhodes T, Twentyman PR.
    Br J Cancer; 1992 May 04; 65(5):684-90. PubMed ID: 1316774
    [Abstract] [Full Text] [Related]

  • 3. Role of RLIP76 in lung cancer doxorubicin resistance: III. Anti-RLIP76 antibodies trigger apoptosis in lung cancer cells and synergistically increase doxorubicin cytotoxicity.
    Awasthi S, Singhal SS, Singhal J, Yang Y, Zimniak P, Awasthi YC.
    Int J Oncol; 2003 Apr 04; 22(4):721-32. PubMed ID: 12632061
    [Abstract] [Full Text] [Related]

  • 4. Transport of the glutathione conjugate of ethacrynic acid by the human multidrug resistance protein MRP.
    Zaman GJ, Cnubben NH, van Bladeren PJ, Evers R, Borst P.
    FEBS Lett; 1996 Aug 05; 391(1-2):126-30. PubMed ID: 8706899
    [Abstract] [Full Text] [Related]

  • 5. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.
    van der Graaf WT, de Vries EG, Timmer-Bosscha H, Meersma GJ, Mesander G, Vellenga E, Mulder NH.
    Cancer Res; 1994 Oct 15; 54(20):5368-73. PubMed ID: 7923167
    [Abstract] [Full Text] [Related]

  • 6. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
    Marbeuf-Gueye C, Broxterman HJ, Dubru F, Priebe W, Garnier-Suillerot A.
    Mol Pharmacol; 1998 Jan 15; 53(1):141-7. PubMed ID: 9443942
    [Abstract] [Full Text] [Related]

  • 7. Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76.
    Awasthi S, Singhal SS, Singhal J, Cheng J, Zimniak P, Awasthi YC.
    Int J Oncol; 2003 Apr 15; 22(4):713-20. PubMed ID: 12632060
    [Abstract] [Full Text] [Related]

  • 8. Role of RLIP76 in lung cancer doxorubicin resistance: I. The ATPase activity of RLIP76 correlates with doxorubicin and 4-hydroxynonenal resistance in lung cancer cells.
    Singhal SS, Singhal J, Sharma R, Singh SV, Zimniak P, Awasthi YC, Awasthi S.
    Int J Oncol; 2003 Feb 15; 22(2):365-75. PubMed ID: 12527936
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
    Perez-Soler R, Neamati N, Zou Y, Schneider E, Doyle LA, Andreeff M, Priebe W, Ling YH.
    Int J Cancer; 1997 Mar 28; 71(1):35-41. PubMed ID: 9096663
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway.
    Shinoda C, Maruyama M, Fujishita T, Dohkan J, Oda H, Shinoda K, Yamada T, Miyabayashi K, Hayashi R, Kawagishi Y, Fujita T, Matsui S, Sugiyama E, Muraguchi A, Kobayashi M.
    Int J Cancer; 2005 Oct 20; 117(1):21-31. PubMed ID: 15880572
    [Abstract] [Full Text] [Related]

  • 15. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995 Oct 20; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

  • 16. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells.
    Perez-Soler R, Ling YH, Zou Y, Priebe W.
    Cancer Chemother Pharmacol; 1994 Oct 20; 34(2):109-18. PubMed ID: 8194162
    [Abstract] [Full Text] [Related]

  • 17. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
    Zaja R, Caminada D, Loncar J, Fent K, Smital T.
    Toxicol Appl Pharmacol; 2008 Mar 01; 227(2):207-18. PubMed ID: 18076962
    [Abstract] [Full Text] [Related]

  • 18. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
    Lehne G, De Angelis P, Clausen OP, Rugstad HE.
    Br J Cancer; 1996 Dec 01; 74(11):1719-29. PubMed ID: 8956784
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
    Majumder S, Dutta P, Mookerjee A, Choudhuri SK.
    Chem Biol Interact; 2006 Feb 01; 159(2):90-103. PubMed ID: 16289015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.